CoChat

Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin

Lambert, Marie, Lupien, Paul-J, Gagné, Claude, Lévy, Emile, Blaichman, Shirley, Langlois, Sylvie, Hayden, Michael, Rose, Vera, Clarke, Joe T. R., Wolfe, Bernard M. J., Clarson, Cheril, Parsons, Howard, Stephure, David K, Potvin, Diane, Lambert, Jean, Canadian Lovastatin in Children Study Group · 1996 · Pediatrics
Cited by 157

The DOI matches its Crossref record.

Abstract

Objective. Familial hypercholesterolemia (FH), an inherited autosomal dominant disorder of lipoprotein metabolism, is associated with premature atherosclerosis. The recommended pediatric therapy consists of dietary intervention and, when necessary, treatment with bile acid-binding resins. However, compliance has been poor in many children. Therefore, our objectives were to determine the efficacy, safety, and tolerance of the short-term use of lovastatin, a 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitor, in the control of severe FH in a male pediatric population and to evaluate the dose-response relationship. Methods. Sixty-nine male patients with FH 12.9 ± 2.4 years of age (mean ± SD) participated in this multicenter, randomized, double-blind trial. After a 4-week placebo period, the patients were allocated to four treatment groups (lovastatin 10, 20, 30, or 40 mg/d) for 8 weeks. Plasma lipid and apolipoprotein (Apo) concentrations were measured every 2 weeks. Clinical and laboratory evidence of adverse events was monitored periodically throughout the study. Results. All lovastatin doses reduced total cholesterol (—17% to —29%), low-density lipoprotein cholesterol (—21% to —36%), and ApoB (—19% to —28%) concentrations. A dose-response relationship was seen, and between-group comparisons showed that results were significantly improved up to a dose of 30 mg/d. We observed a 7% increase in high-density lipoprotein cholesterol and a 4% increase in ApoA1 concentrations. The medication was well tolerated by all patients. No serious clinical adverse experience was reported. Lovastatin increased aspartate aminotransferase concentrations, but there was no evidence of a dose-response relationship, and no value exceeded two times the upper limit of normal. No significant change in alanine aminotransferase was observed. Three patients had marked (more than three times the upper limit of normal) asymptomatic elevations in their creatine kinase values, which returned spontaneously to normal, and no action was required regarding the drug. Conclusions. Lovastatin is an effective therapy for severe FH in children and adolescents. It was well tolerated, and the occurrence of adverse experiences of clinical significance was very low. Long-term pediatric studies are indicated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.97.5.619

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 157

Metadata

Authors
Lambert, M., Lupien, P.-J., Gagné, C., Lévy, E., Blaichman, S., Langlois, S., Hayden, M., Rose, V., Clarke, J. T. R., Wolfe, B. M. J., Clarson, C., Parsons, H., Stephure, D. K., Potvin, D., Lambert, J., & Canadian Lovastatin in Children Study Group
Venue
Pediatrics
Published
1996-05-01
Volume
97
Issue
5
Pages
619-628
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W1934245552
Cited by
157
References
0
FWCI
2.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin. https://app.cochat.ai/papers/10.1542/peds.97.5.619
The paper
Lambert, M., Lupien, P.-J., Gagné, C., Lévy, E., Blaichman, S., Langlois, S., Hayden, M., Rose, V., Clarke, J. T. R., Wolfe, B. M. J., Clarson, C., Parsons, H., Stephure, D. K., Potvin, D., Lambert, J., & Canadian Lovastatin in Children Study Group. (1996). Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin. Pediatrics. https://doi.org/10.1542/peds.97.5.619

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.